Antibodies to early EBV, CMV, and HHV6 antigens in systemic lupus erythematosus patients

Scandinavian Journal of Rheumatology

Volumn 44, Issue 2, 2015, Pages 143-149

  Rasmussen, N ^a   Draborg, A ^a   Nielsen, C ^b   Jacobsen, S ^b   Houen, G ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; CYTOMEGALOVIRUS ANTIGEN PP52; DNA POLYMERASE; EARLY ANTIGEN; EARLY ANTIGEN DIFFUSE; EPSTEIN BARR VIRUS ANTIBODY; EPSTEIN BARR VIRUS ANTIGEN; HUMAN HERPESVIRUS 6 ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; PROTEIN P41; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; HUMAN; HUMAN HERPESVIRUS 6; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROLOGY; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS REACTIVATION; BLOOD; CASE CONTROL STUDY; DENMARK; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

ADULT; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CASE-CONTROL STUDIES; CYTOMEGALOVIRUS; DENMARK; FEMALE; HERPESVIRUS 4, HUMAN; HERPESVIRUS 6, HUMAN; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; SEVERITY OF ILLNESS INDEX;

EID: 84928823584     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2014.973061     Document Type: Article

References (35)

1. Gordon C, Li CK, Isenberg DA. Systemic lupus erythematosus. Medicine 2009;38:73-80
2. Tsao BP. The genetics of human systemic lupus erythematosus. Trends Immunol 2003;24:595-602
3. Sarzi-Puttini P, Atzeni F, Laccarino L, Doria A. Environment and systemic lupus erythematosus: an overview. Autoimmunity 2005;38:465-72
4. Draborg AH, Duus K, Houen G. Epstein-Barr virus and systemic lupus erythematosus. Clin Dev Immunol 2012;2012:370516.
5. Braun DK, Dominguez G, Pellett PE. Human herpesvirus 6. Clin Microbiol Rev 1997;10:521-67
6. Penkert RR, Kalejta RF. Tegument protein control of latent herpesvirus establishment and animation. Herpesviridae 2011;2:3
7. Oster B, Hollsberg P. Viral gene expression patterns in human herpesvirus 6B-infected T cells. J Virol 2002;76:7578-86
8. Lin K, Ricciardi RP. The 41-kDa protein of human herpesvirus 6 specifically binds to viral DNA polymerase and greatly increases DNA synthesis. Virology 1998;250:210-19
9. Weiland KL, Oien NL, Homa F, Wathen MW. Functional analysis of human cytomegalovirus polymerase accessory protein. Virus Res 1994;34:191-206
10. Kiehl A, Dorsky DI. Bipartite DN A-binding region of the Epstein- Barr virus BMRF1 product essential forDNApolymerase accessory function. J Virol 1995;69:1669-77
11. De Paschale M, Cagnin D, Cerulli T, Manco MT, Agrappi C, Mirri P, et al. Search for anti-EA(D) antibodies in subjects with an 'isolated VCA IgG' pattern. Int J Microbiol 2010;2010:695104
12. Ooka T, Turenne-Tessier MD, Stolzenberg MC. Relationship between antibody production to Epstein-Barr virus (EBV) early antigens and various EBV-related diseases. Springer Semin Immunopathol 1991;13:233-47
13. Henle W, Henle G. EBV-specific serology in immunologically compromised individuals. Cancer Res 1981;41:4222-5
14. Musiani M, Carpi C, Zerbini M. Rapid detection of antibodies against cytomegalovirus induced immediate early and early antigens by an enzyme linked immunosorbent assay. J Clin Pathol 1984;37:122-5
15. Draborg AH, Jorgensen JM, Muller H, Nielsen CT, Jacobsen S, Iversen LV, et al. Epstein-Barr virus early antigen diffuse (EBV EA/D)-directed immunoglobulin A antibodies in systemic lupus erythematosus patients. Scand J Rheumatol 2012;41:280-9
16. Stratta P, Canavese C, Ciccone G, Santi S, Quaglia M, Ghisetti V, et al. Correlation between cytomegalovirus infection and Raynaud's phenomenon in lupus nephritis. Nephron 1999;82:145-54
17. Esen BA, Yilmaz G, Uzun S, Ozdamar M, Aksö A, Kamali S, et al. Serologic response to Epstein-Barr virus antigens in patients with systemic lupus erythematosus: a controlled study. Rheumatol Int 2012;32:79-83
18. Zandman-Goddard G, Berkun Y, Barzilai O, Boaz M, Blank M, Ram M, et al. Exposure to Epstein-Barr virus infection is associated with mild systemic lupus erythematosus disease. Ann N Y Acad Sci 2009;1173:658-63
19. Huggins ML, Todd I, Powell RJ. Reactivation of Epstein-Barr virus in patients with systemic lupus erythematosus. Rheumatol Int 2005;25:183-7
20. Berkun Y, Zandman-Goddard G, Barzilai O, Boaz M, Sherer Y, Larida B, et al. Infectious antibodies in systemic lupus erythematosus patients. Lupus 2009;18:1129-35
21. Broccolo F, Drago F, Cassina G, Fava A, Fusetti L, Matteoli B, et al. Selective reactivation of human herpesvirus 6 in patients with autoimmune connective tissue diseases. JMed Virol 2013;85:1925-34
22. Su BY, Su CY, Yu SF, Chen CJ. Incidental discovery of high systemic lupus erythematosus disease activity associated with cytomegalovirus viral activity. Med Microbiol Immunol 2007;196:165-70
23. Hochberg MC. Updating the American College of Rheumatology Revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725
24. Larsen M, Sauce D, Deback C, Arnaud L, Mathian A, Miyara M, et al. Exhausted cytotoxic control of Epstein-Barr virus in human lupus. PLoS Pathog 2011;7:1371
25. Vilá LM, Alarcón GS, McGwin G Jr, Bastian HM, Fessler BJ, Reveille JD, et al. Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual. Arthritis Rheum 2006;55:799-806
26. Utsinger PD. Relationship of lymphocytotoxic antibodies to lymphopenia and parameters of disease activity in systemic lupus erythematosus. J Rheumatol 1976;3:175-85
27. Mirzayan MJ, Schmidt RE, Witte T. Prognostic parameters for flare in systemic lupus erythematosus. Rheumatology 2000; 39:1316-19
28. Quan TE, Roman RM, Rudenga BJ, Holers VM, Craft JE. Epstein- Barr virus promotes interferon-Alpha production by plasmacytoid dendritic cells. Arthritis Rheum 2010;62:1693-701
29. Severa M, Giacomini E, Gafa V, Anastasiadou E, Rizzo F, Corazzari M, et al. EBV Stimulates TLR- and autophagydependent pathways and impairs maturation in plasmacytoid dendritic cells: implications for viral immune escape. Eur J Immunol 2013;43:147-58
30. Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000;9:664-71
31. Kim T, Kanayama Y, Negoro N, Okamura M, Takeda T, Inoue T. Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol 1987;70:562-9
32. Schattner A. Lymphopenia in systemic lupus erythematosus: possible role of interferon. Arthritis Rheum 1983;26:1415
33. Groux H, Cottrez F, Montpellier C, Quatannens B, Coll J, Stehelin D. Isolation and characterization of transformed human T-cell lines infected by Epstein-Barr virus. Blood 1997;89:4521-30
34. Schneider K, Meyer-Koenig U, Hufert FT. Human cytomegalovirus impairs the function of plasmacytoid dendritic cells in lymphoid organs. PLoS One 2008;3:3482
35. Chang WLW, Barry PA, Szubin R, Wang D, Baumgarth N. Human cytomegalovirus suppresses type 1 interferon secretion by plasmacytoid dendritic cells through its interleukin 10 homolog. Virology 2009;390:330-7